Bristol Myers Squibb earnings date
Bristol Myers Squibb's next results are expected on October 29, 2026. Watch whether launch investment is producing patient uptake.
What has Bristol Myers Squibb guided for 2026?
Guidance is management’s forecast. On July 30, BMS raised its full-year revenue range to $49,000–$50,000 million and its diluted non-GAAP EPS range to $6.75–$7.00. Non-GAAP EPS excludes specified accounting items; diluted EPS also allows for shares that could be issued through instruments such as employee awards.
BMS also targets $2,000 million in annual savings by December 2027, alongside $2,500 million of restructuring charges. The test is whether those savings create room for productive research rather than weaken it.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| Total Revenues(Reported & Ex-FX) | Year to Dec 2026 | 49,000 | 50,000 | Jul 30, 2026 |
| Operating Expenses | Year to Dec 2026 | 16,500 | 16,500 | Jul 30, 2026 |
| Diluted EPS | Year to Dec 2026 | 6.75 | 7.00 | Jul 30, 2026 |
| annual cost savings | By Dec 2027 | 2,000 | 2,000 | Jul 30, 2026 |
What this means. The negative 700 million dollars for other income or expense means the company expects this item to reduce profit, not increase it.
Did Bristol Myers Squibb keep its past promises?
Management has delivered some narrower promises. In February 2025 it forecast about US$45.5 billion of annual revenue; the eventual result was US$48.194 billion. It also committed to repay about US$10 billion of debt by 2026 and reported achieving that goal by the end of 2025.
What are Bristol Myers Squibb's recent revenue and profit results?
Revenue increased 5.7%, while diluted EPS rose much faster. The acquired-research and licensing contribution moved from a negative $0.57 per share in the earlier quarter to a positive $0.01. Excluding that effect gives a like-for-like EPS comparison of approximately $1.61 against $1.21. The headline improvement therefore overstates the commercial improvement.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12,973 | 11,489 | 12,502 | 12,222 | 12,269 | 11,201 | 12,342 | 11,892 |
| Gross margin | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | 72.9% | 61.0% | 75.1% |
| Operating income | 4,025 | 3,271 | 1,419 | 3,006 | 2,266 | 3,309 | 480 | 1,910 |
| Net income | 3,317 | 2,677 | 1,087 | 2,201 | 1,310 | 2,456 | 72 | 1,211 |
| EPS, diluted | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | 1.20 | 0.04 | 0.60 |
What this means. The gross margin leaves out the gradual expense from acquired intangible assets, so it is not the same as the profit the company ultimately keeps.
What should Bristol Myers Squibb watch in its next results?
BMS is scheduled to report its third quarter on October 29, 2026. That report should separate ordinary trading from collaboration charges and show whether launch investment is producing patient uptake.